SynthesisFrontiers in pharmacology2025
Biochemical changes associated with non-alcoholic fatty liver disease in response to berberine treatment: a systematic review and meta-analysis of clinical and preclinical research.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Preclinical evaluation of puerarin for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis.Frontiers in pharmacology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) represents a global health challenge. Berberine, an isoquinoline alkaloid traditionally used for metabolic disorders, has garnered attention for its potential therapeutic interventions. Objective: To comprehensively review and perform a meta-analysis of berberine's effects on NAFLD across clinical and preclinical studies. Methods: A comprehensive literature search was conducted across five databases from their inception to May 2024. We included randomized controlled trials and animal studies that evaluated berberine's impact on NAFLD using specified biochemical markers. Results: Out of 487 screened studies, 22 (4 clinical and 18 preclinical) were included. Clinically, berberine significantly reduced fasting blood glucose (FBG) levels, with an effect size of 0.53 (95% CI: 0.04-1.01). In preclinical settings, berberine consistently demonstrated benefits across several markers, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lipid profiles, despite significant heterogeneity in some outcomes. Conclusion: Berberine presents promising therapeutic avenues for NAFLD management, especially in terms of glucose metabolism. Further rigorous, well-designed trials are needed to substantiate these findings. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, Identifier CRD42023459618.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.